Selank: A Research Overview of the Tuftsin-Derived Heptapeptide in 2026

Selank belongs to a small family of research peptides that came out of a specific institutional tradition: the Institute of Molecular Genetics of the Russian Academy of Sciences, where a program running from the 1980s onward set out to build stable synthetic analogs of short endogenous regulatory peptides. The design philosophy behind that program produced Selank and its structural cousin Semax, and understanding the philosophy explains a great deal about how both molecules behave in experimental systems.

For in-vitro laboratory research use only. Not for human consumption.

The Design Problem the Program Set Out to Solve

Short endogenous peptides are attractive as research tools because they act on receptor systems the organism already uses, at concentrations the organism already tolerates. Their liability is that they survive for seconds. Aminopeptidases at the N-terminus, carboxypeptidases at the C-terminus, and endopeptidases throughout the chain reduce an unmodified tetrapeptide to constituent amino acids almost immediately in plasma or tissue homogenate. An unmodified regulatory peptide is nearly useless as an experimental probe because you cannot maintain a defined exposure.

The Institute's approach was to append a Pro-Gly-Pro tripeptide to the C-terminus of the active fragment. The rationale is structural. Proline is the only proteinogenic amino acid whose side chain closes back onto the backbone nitrogen, forming a rigid five-membered ring. That ring constrains the backbone conformation and, critically, makes the peptide bond on either side of proline a poor substrate for most peptidases — the enzymes cannot accommodate the constrained geometry in their active sites. Flanking a glycine with two prolines produces a C-terminal cap that is close to protease-resistant while adding minimal steric bulk.

Selank is the result of applying this strategy to tuftsin.

Tuftsin: The Parent Molecule

Tuftsin is an endogenous tetrapeptide, Thr-Lys-Pro-Arg, corresponding to residues 289–292 of the heavy chain of immunoglobulin G. It is not synthesized as a free peptide; it is released enzymatically from the IgG Fc region by the action of two proteases — one splitting the C-terminal bond in the spleen, the other cleaving the N-terminal bond at the surface of phagocytic cells. It was named for Tufts University, where it was characterized in the 1970s.

Tuftsin's originally described activity was immunological: it stimulates phagocytosis by macrophages and neutrophils, enhances antigen presentation, and modulates cytokine output. Subsequent work identified tuftsin receptor expression on microglia — the resident immune cells of the central nervous system — which brought the peptide into neuroscience research.

Free tuftsin has a plasma half-life measured in tens of seconds. Selank was constructed to preserve the tuftsin pharmacophore while surviving long enough to be studied.

Structure

Selank is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, with a molecular weight near 752 g/mol. The first four residues are tuftsin; the last three are the stabilizing cap. In the literature it also appears as TP-7.

Points of structural interest for experimental work:

• Net positive charge. The lysine and arginine residues give the peptide a net charge of +2 at physiological pH, which affects its behavior on ion-exchange chromatography and its adsorption to negatively charged surfaces.
• Three prolines out of seven residues. This is an unusually high proline content and produces a peptide with restricted conformational freedom — closer to a rigid rod than a flexible chain. Circular dichroism spectra reflect this, showing polyproline-II character rather than the random-coil signature typical of short peptides.
• No cysteine, no aromatic residues except through the arginine guanidinium. The absence of tryptophan and tyrosine means the peptide has very weak absorbance at 280 nm, which matters practically: quantification by UV absorbance at that wavelength is unreliable and concentration should be established by amino acid analysis or by weight with correction for net peptide content.

Mechanistic Research Domains

Selank does not have a single identified high-affinity receptor in the way that a classical ligand does. The preclinical literature instead describes a set of system-level effects, each supported by direct measurement, and mechanistic work has focused on characterizing those effects rather than on identifying one binding site.

GABAergic Modulation

The most frequently cited research domain concerns the GABA system. Studies in rodent models report changes in the expression of GABA-A receptor subunits in limbic structures following Selank administration, together with changes in GABA-binding characteristics measured in membrane preparations from those regions.

What makes this line of work notable in the literature is the behavioral profile that accompanies it. Benzodiazepine reference compounds, which act as positive allosteric modulators at the GABA-A receptor, produce anxiolytic-like effects in rodent paradigms but also produce sedation, motor impairment, and, on withdrawal after chronic exposure, rebound effects. Kozlovskii and Danchev (2003) and subsequent work reported that Selank produces anxiolytic-like effects in validated paradigms — elevated plus maze, open field, conflict tests — without the accompanying sedation or motor impairment in the same animals. This dissociation is the finding that has driven most of the interest in the compound as a research tool: it suggests the GABAergic effect is indirect or subunit-selective rather than a direct positive allosteric action at the benzodiazepine site.

Monoamine Turnover

A second body of work examines serotonergic and dopaminergic systems. Microdialysis and post-mortem tissue analysis studies in rat models have reported changes in serotonin concentration and in the ratio of the metabolite 5-HIAA to serotonin — an index of turnover rate — in the hippocampus, amygdala, and hypothalamus following Selank administration.

The direction and magnitude of these changes vary by region and by the strain and stress state of the animal, which is informative. It suggests the peptide is modulating an existing regulatory tone rather than driving a system in one fixed direction, which is a pattern more typical of neuropeptides than of classical small-molecule neurotransmitter drugs.

BDNF Expression

Brain-derived neurotrophic factor is the most abundant neurotrophin in the mammalian brain and a central mediator of activity-dependent synaptic plasticity. Volkova and colleagues (2016) reported that Selank administration increased BDNF expression in rat hippocampus, measured at both the transcript and protein levels.

This finding connects Selank to a research literature much larger than the peptide itself. BDNF-TrkB signaling is a convergence point for a wide range of interventions studied in models of stress, plasticity, and neuronal survival, and a compound that reproducibly modulates hippocampal BDNF is useful as a tool regardless of what other mechanisms it engages.

Enkephalin-Degrading Enzyme Activity

Selank has been reported to inhibit the enzymes that degrade endogenous enkephalins in plasma and in brain tissue preparations. The consequence would be an extended lifetime for endogenous opioid peptides rather than any direct action at opioid receptors — an indirect mechanism that is difficult to distinguish from direct receptor engagement in behavioral assays alone, and one reason careful studies in this area include receptor antagonist controls.

Immune and Gene Expression Effects

Because Selank retains the tuftsin pharmacophore, immunological activity would be expected, and it has been reported. Studies describe effects on cytokine expression profiles — notably interleukin-6 — and on interferon-related gene expression in leukocyte preparations.

Kolomin and colleagues (2013) took a broader approach, using transcriptome analysis to characterize gene expression changes in rat brain and blood following Selank administration. The reported result was coordinated changes across clusters of genes related to immune signaling and neurotransmitter metabolism rather than a small number of large individual changes. This pattern — distributed modest effects across functionally related gene sets — is characteristic of regulatory peptides and is one reason single-pathway experimental designs often fail to capture what these compounds do.

Selank and Semax: A Structural Comparison

The two peptides come from the same design program and share the C-terminal Pro-Gly-Pro cap, which leads to their being grouped together and sometimes conflated. The active fragments are entirely different molecules with different origins.

The shared cap means they share handling characteristics and analytical challenges. Their mechanisms are not interchangeable, and studies that treat them as a single class of "Russian nootropic peptides" are grouping by provenance rather than by pharmacology.

Analytical Verification

Selank presents a specific analytical profile that researchers should understand when reading a certificate of analysis.

Purity by reverse-phase HPLC. The research-grade floor is ≥99%. Proline-rich peptides can show broadened or split peaks on reverse-phase columns because cis-trans isomerization about the proline peptide bonds occurs on a timescale comparable to chromatographic separation. With three prolines, Selank can display this behavior. A slightly broadened peak is not necessarily an impurity — but distinguishing conformational broadening from genuine heterogeneity requires either elevated column temperature, which speeds isomerization into the fast-exchange regime, or orthogonal confirmation by mass spectrometry.

Identity by mass spectrometry. The theoretical monoisotopic mass should be stated alongside the observed value. The most likely synthesis defects — a deleted proline, an incomplete coupling at one of the hindered proline positions — produce mass differences that are unambiguous by MS.

Weak UV absorbance. With no tryptophan or tyrosine, Selank absorbs poorly at 280 nm. HPLC detection is typically at 214–220 nm, monitoring the peptide bond itself. This is a less selective wavelength, so buffer components and scavengers from the cleavage step absorb there too. A clean baseline in that region indicates thorough purification.

Counterion and net peptide content. Peptides purified by reverse-phase HPLC with trifluoroacetic acid in the mobile phase carry TFA counterions, which can be 10–20% of the gross weight for a peptide with two basic residues. Experiments requiring accurate molar concentration must use net peptide content, not vial fill weight. Some research applications are sensitive to residual TFA, in which case acetate salt exchange should be specified and documented.

Handling and Storage

Lyophilized Selank should be stored at -20°C, protected from light and moisture, and kept lyophilized until required.

General handling considerations:

• Equilibrate vials to room temperature before opening to prevent condensation onto the lyophilized cake.
• Aliquot at the time of first reconstitution. Repeated freeze-thaw cycling degrades short peptides and introduces variance that is easy to misattribute to biology.
• Use low-binding labware for dilute preparations. A +2-charged peptide adsorbs measurably to standard plastics at low concentrations.
• Note that the proline-rich backbone is relatively resistant to enzymatic degradation but not to chemical hydrolysis. Extremes of pH, particularly at elevated temperature, will cleave the chain.

This site does not publish reconstitution protocols, dosing guidance, or administration procedures. Those determinations belong to the researcher operating under an approved protocol.

Reading the Selank Literature

Several practical issues affect literature review for this compound.

Language and indexing. A substantial portion of the primary Selank literature was originally published in Russian-language journals, some of which are indexed with translated titles and some of which are not indexed in the major English-language databases at all. A PubMed search on "Selank" returns a real but incomplete picture of the field. Searching "TP-7" and the Russian transliteration variants recovers additional work.

Model heterogeneity. Studies use different rodent strains, and several use strains selectively bred for high or low anxiety-like behavior. Effect sizes are not comparable across these systems, and a result in a high-anxiety-selected strain does not predict a result in a standard outbred stock.

Route and formulation. Much of the published work uses intranasal administration, which for a peptide of this size and charge produces a different exposure profile than systemic routes. Comparing across routes without accounting for this is a common source of apparent inconsistency.

Endpoint selection. Anxiolytic-like behavior in rodents is inferred from proxy measures — time in the open arms of an elevated plus maze, latency to enter a lit compartment — each of which is sensitive to handling, lighting, time of day, and prior test experience. Studies that report a single behavioral endpoint without locomotor controls cannot distinguish an anxiolytic-like effect from a general change in activity.

Publication era. The bulk of the mechanistic work dates from the 1990s and 2000s. Analytical standards, statistical practice, and reporting conventions have changed since, and older papers frequently lack the sample size justification and blinding disclosures that current standards expect. This does not invalidate the findings but does affect how much weight a single study should carry.

Experimental Readouts Used in Selank Studies

Selank's effects are distributed across several systems, so studies typically combine behavioral, neurochemical, and molecular endpoints rather than relying on one measurement.

Validated rodent anxiety-like paradigms. The elevated plus maze remains the most frequently used, measuring time spent in and entries into the open arms as a proxy for approach-avoidance conflict. The light-dark box and open field arena serve similar functions with different sensory demands. Each is sensitive to handling history, ambient light level, circadian phase, and whether the animal has seen the apparatus before, which is why well-designed studies randomize test order and report the testing conditions explicitly.

Locomotor controls. Any behavioral claim in this domain requires a separate measure of general activity. A compound that reduces movement will increase open-arm time in the plus maze for reasons unrelated to anxiety-like state. Total distance traveled in an open field, or total arm entries in the maze, distinguishes the two. The absence of a locomotor control is the single most common weakness in older reports.

Rotarod and motor coordination testing. Because the dissociation between anxiolytic-like effect and sedation is the central claim in the Selank literature, motor coordination testing carries unusual weight here. A benzodiazepine comparator run in parallel provides the positive control for sedation, establishing that the assay is sensitive enough to detect impairment if it were present.

Microdialysis. Freely moving animals with implanted probes allow serotonin, dopamine, and their metabolites to be sampled in defined brain regions over time. This is the most direct measurement of monoamine turnover and the one most resistant to post-mortem artifacts, though it is technically demanding and limited in spatial resolution.

Post-mortem tissue neurochemistry. HPLC with electrochemical detection on dissected regions quantifies monoamines and metabolites. The 5-HIAA/5-HT ratio is the standard turnover index. This approach gives better anatomical resolution than microdialysis but only a single time point per animal.

Receptor binding and subunit expression. Radioligand binding on membrane preparations characterizes GABA-A receptor density and affinity. Quantitative PCR or immunoblotting for individual subunits addresses the subunit-composition hypothesis that would explain a non-sedating GABAergic profile.

BDNF quantification. ELISA on tissue homogenate for protein, quantitative PCR for transcript. Measuring both matters because BDNF is subject to substantial post-transcriptional regulation, and transcript changes do not always translate to protein changes on the same timescale.

Transcriptome profiling. Microarray or RNA-sequencing approaches, as used in the Kolomin work, capture the distributed modest changes characteristic of regulatory peptides. Analysis at the gene-set level rather than the individual-gene level is generally more informative for this class of compound.

Common Pitfalls in Selank Experimental Design

Quantifying by UV absorbance at 280 nm. Selank contains no tryptophan and no tyrosine. Absorbance at 280 nm is negligible, and a concentration derived from it will be badly wrong. Quantification should use amino acid analysis, or gravimetry corrected for net peptide content and counterion mass.

Ignoring counterion mass. With two basic residues, TFA counterions can account for a substantial fraction of vial fill weight. Studies that report concentration based on gross weight are systematically overestimating molar concentration, and by an amount that varies between lots and between suppliers.

Misreading proline isomerization as impurity. Split or broadened HPLC peaks are an expected consequence of three prolines in a seven-residue chain. Rejecting a lot on this basis without running the column at elevated temperature or confirming by mass spectrometry discards good material; accepting genuinely heterogeneous material because "prolines do that" accepts bad material. Both errors are avoided by orthogonal confirmation.

Comparing across administration routes. Intranasal, intraperitoneal, and intravenous administration produce very different exposure profiles for a charged heptapeptide. Effect sizes are not transferable between them, and much of the apparent inconsistency in the literature dissolves once route is accounted for.

Using anxiety-selected strains without acknowledging it. Several studies use rodent lines selectively bred for extreme anxiety-like phenotypes. These strains have altered baseline GABAergic and monoaminergic tone, and effect sizes measured in them do not predict effects in standard outbred stock.

Single-endpoint designs. Given that the compound acts through distributed modest changes across several systems, a study measuring one endpoint has a high probability of missing the effect entirely, and a correspondingly high probability of reporting a false negative.

Assuming direct receptor engagement. Selank has no identified high-affinity receptor. Behavioral effects blocked by a GABA-A antagonist are consistent with GABAergic involvement but do not establish direct binding. Distinguishing indirect modulation from direct action requires binding studies, not behavioral pharmacology alone.

A further practical note on interpretation: because Selank's reported effects are modest in magnitude and distributed across several systems, statistical power is a recurring limitation in this literature. Many published studies use group sizes appropriate for detecting large effects and are underpowered for the effect sizes they actually report. A single small study showing an effect, and a single small study failing to show one, are both weak evidence. Researchers planning new work with this compound should size groups against the effect magnitudes reported in the better-powered studies rather than against the largest reported values, and should pre-register the primary endpoint so that the multiple-comparison problem inherent in multi-system readouts does not silently inflate the apparent result.

Where Selank Fits Among Research Tools

Selank is most useful experimentally as a probe for indirect GABAergic modulation — a system-level intervention that produces anxiolytic-like behavioral outcomes without the sedation signature of direct positive allosteric modulators. That dissociation is the interesting scientific question, and it is what makes the compound worth studying rather than simply using a benzodiazepine reference compound.

Researchers assembling a neuropeptide research panel typically pair it with Semax, which shares the stabilizing cap but engages neurotrophic rather than GABAergic mechanisms. The two together allow a study to separate effects attributable to the Pro-Gly-Pro scaffold and general peptide handling from effects attributable to the specific active fragment — a control that is difficult to construct any other way.

The Pro-Gly-Pro Cap as an Experimental Variable

One design feature deserves separate discussion because it is frequently treated as inert and is not. The C-terminal Pro-Gly-Pro extension was added to Selank for a purely pharmacokinetic reason: to block peptidase access to the tuftsin core. But a tripeptide appended to a tetrapeptide is not a small perturbation. It nearly doubles the molecular weight, changes the hydrodynamic radius, alters the charge distribution along the chain, and imposes a polyproline-II conformation on a molecule that would otherwise be conformationally free.

Several consequences follow for experimental interpretation.

Selank is not simply "stable tuftsin." Its activity profile overlaps tuftsin's but is not identical, and studies that use tuftsin data as a proxy for Selank mechanism are making an assumption the structural change does not license. Where a study needs to distinguish tuftsin-attributable effects from Selank-specific effects, both compounds must be run.

The Pro-Gly-Pro fragment is itself biologically active. The free tripeptide has been described in the literature as having its own effects, including on hemostasis and gastric mucosal parameters. Whether the cap is released intact during metabolism of Selank, and whether any released fragment contributes to observed effects, is a question that most studies do not address. A researcher interpreting an unexpected result should hold this possibility open.

The same cap is present in Semax. This is why the pairing of the two compounds is a useful control rather than merely a convenient product-line grouping. Effects common to both are candidates for cap-attributable or handling-attributable phenomena; effects unique to one are candidates for active-fragment-attributable mechanism. Running only one of the pair forecloses that comparison.

Conformational rigidity affects binding kinetics. A polyproline-II rod has far less conformational entropy to lose on binding than a flexible chain. This generally favors faster association and can improve apparent affinity, but it also means the molecule cannot adopt induced-fit conformations that a flexible peptide could. Where the tuftsin core would need to bend to engage a binding site, the capped version may not be able to.

These are not reasons to avoid the compound. They are reasons to describe it accurately in methods sections and to avoid the shorthand that treats the cap as a purely pharmacokinetic modification with no pharmacodynamic consequence.

Sourcing Considerations

The proline content that makes Selank stable in biological systems also makes it more difficult to synthesize cleanly. Proline-proline couplings are slow, sterically hindered, and prone to incomplete reaction under compressed synthesis schedules. The resulting deletion sequences differ from the target by one residue — 97 Da for a missing proline — which mass spectrometry detects readily but which a purity number alone will not surface if the chromatographic gradient is too steep to resolve the species.

What to require from a supplier:

• Independent third-party analysis, from a laboratory with no financial stake in the outcome.
• Both HPLC and MS on the specific lot shipped, with theoretical and observed masses stated numerically.
• The chromatogram itself, so peak shape and baseline can be assessed rather than taken on trust — particularly important here given the proline isomerization behavior.
• Lot-matched documentation. The identifier on the certificate and the identifier on the vial must be the same.
• Counterion disclosure, and acetate exchange where the research application requires it.
• Controlled shipping. Lyophilized peptide is robust, but sustained heat in transit accelerates degradation.

Excalibur Peptides supplies Selank at ≥99% HPLC-verified purity with an independent, batch-level certificate of analysis, shipped from a United States facility. Material that does not meet the ≥99% floor is not released.

Frequently Asked Questions

What is Selank?

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built from the endogenous immunomodulatory tetrapeptide tuftsin with a Pro-Gly-Pro stabilizing extension. It is studied in preclinical models for GABAergic modulation, monoamine turnover, and BDNF expression. It is supplied strictly for in-vitro laboratory research and is not for human consumption.

What is Selank derived from?

The active portion of Selank is tuftsin, a tetrapeptide released enzymatically from the heavy chain of immunoglobulin G. The added Pro-Gly-Pro tripeptide confers resistance to peptidase degradation.

How is Selank different from Semax?

Both share the Pro-Gly-Pro stabilizing cap and came from the same research program, but their active fragments are unrelated. Selank is built on tuftsin and is studied mainly for GABAergic and immunomodulatory effects; Semax is built on the ACTH(4-7) fragment and is studied mainly for neurotrophic effects on BDNF and NGF.

What purity should research-grade Selank meet?

The research-grade floor is ≥99% by reverse-phase HPLC with identity confirmed by mass spectrometry against the theoretical molecular weight, both reported on a lot-specific certificate of analysis from an independent laboratory.

How should Selank be stored?

Lyophilized Selank should be stored at -20°C, protected from light and moisture, and kept lyophilized until required. Repeated freeze-thaw cycling of prepared solutions should be avoided.

Is Selank approved for human use?

No. Selank is sold strictly for in-vitro laboratory research and identification purposes. It is not approved by the FDA for human therapeutic use, is not intended for veterinary administration, and is not intended for any clinical application.

View the Selank product page · View the Semax product page · Browse the research catalog · View the COA database

All compounds referenced in this article are sold for in-vitro laboratory research purposes only. They are not drugs, supplements, or medical products, and are not intended for human use, veterinary use, or consumption of any kind. Always consult applicable regulations regarding peptide research in your jurisdiction.

Last updated: July 2026